{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:07:41Z","timestamp":1763665661003,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing the majority of all lymphomas arising in the skin. The disease treatment focuses on managing symptoms and preventing disease evolution. To date, there is no gold standard for MF-CTCL treatment. Chlormethine, a DNA alkylating agent, is a long-known treatment for CTCL. The new chlormethine 0.02% gel (CL-gel) formulation provides proven efficacy and ease of application, improving patient compliance and outcome. The current consensus paper and real-world experience with CL-gel in the treatment of early-stage MF-CTCL may help meet the unmet need for treatments in Canada. A modified Delphi process comprised a virtual meeting and an online follow-up. A panel of 9 board-certified dermatologists with expertise in cutaneous lymphoma and 1 radiation oncologist discussed the systematic literature review results, drew from clinical experience and the opinion of the panel to adopt and agree on five consensus statements. The panel shared real-world patient cases to illustrate the use of chlormethine gel in a variety of patients across Canada. Five real-world patient cases were provided to illustrate the panels\u2019 use of chlormethine gel.<\/jats:p>","DOI":"10.3389\/fmed.2024.1474030","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:25:01Z","timestamp":1734355501000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Canadian consensus on chlormethine gel use in mycosis fungoides-CTCL: literature review and real-world experience"],"prefix":"10.3389","volume":"11","author":[{"given":"Ivan V.","family":"Litvinov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohannad","family":"Abu-Hilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raed","family":"Alhusayen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Delisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Dutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gu\u00e9nin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Pehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Roberge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1002\/cncr.30758","article-title":"Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy","volume":"123","author":"Ghazawi","year":"2017","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.critrevonc.2007.08.004","article-title":"Mycosis fungoides","volume":"65","author":"Zinzani","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100069","DOI":"10.1016\/j.xjidi.2021.100069","article-title":"Increased chlormethine-induced DNA double-stranded breaks in malignant T cells from mycosis fungoides skin lesions","volume":"2","author":"Chang","year":"2022","journal-title":"JID Innov"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.jid.2023.03.662","article-title":"655 tumor micro-environment shift induced by topical chlormethine in early-stage mycosis fungoides by flow cytometry of interstitial fluid","volume":"143","author":"Wind","year":"2023","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/jdv.19237","article-title":"Mechanism of action of chlormethine gel in mycosis fungoides","volume":"37","author":"Guenova","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref9","first-page":"1","article-title":"Chlormethine gel for the treatment of mycosis Fungoides (cutaneous T-cell lymphoma) in Canada","volume":"28","author":"Gniadecki","year":"2023","journal-title":"Skin Therapy Lett"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","article-title":"Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience","volume":"11","author":"Geskin","year":"2021","journal-title":"Dermatol Ther"},{"volume-title":"LEDAGA\u2122 (chlormethine gel)","year":"2021","key":"ref11"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-022-00681-6","article-title":"Randomized mechlorethamine\/chlormethine induced dermatitis assessment study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides","volume":"12","author":"Alexander-Savino","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.jaad.2010.10.029","article-title":"American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency","volume":"64","author":"Begolka","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2013update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: results from the PROspective cutaneous lymphoma international prognostic index (PROCLIPI) study","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides: experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/09546634.2021.1967266","article-title":"Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects#","volume":"33","author":"Prag Naveh","year":"2022","journal-title":"J Dermatol Treat"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"adv00544","DOI":"10.2340\/00015555-3911","article-title":"Management of mycosis fungoides with topical chlormethine\/mechlorethamine gel: a Columbia University cutaneous lymphoma center experience","volume":"101","author":"Garcia-Saleem","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e15683","DOI":"10.1111\/dth.15683","article-title":"Topical chlormethine gel in the treatment of mycosis fungoides: a single-center real-life experience and systematic review of the literature","volume":"35","author":"Laghi","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/ddg.14610_g","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"19","author":"Jonak","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s13555-022-00813-y","article-title":"Chlormethine gel for the treatment of mycosis fungoides cutaneous T-cell lymphoma: in vitro release and permeation testing","volume":"12","author":"Giuliano","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1308491","DOI":"10.3389\/fmed.2023.1308491","article-title":"Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases","volume":"10","author":"Ardig\u00f2","year":"2023","journal-title":"Front Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"adv00730","DOI":"10.2340\/actadv.v102.1095","article-title":"Chlormethine gel is efficient and safe in mycosis fungoides skin lesions","volume":"102","author":"Koumourtzis","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","article-title":"Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T cell lymphoma: three case reports","volume":"38","author":"Lampadaki","year":"2021","journal-title":"Adv Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/cco.2018.10.01","article-title":"Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment","volume":"8","author":"Jennings","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.clml.2022.02.002","article-title":"Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single-center retrospective study","volume":"22","author":"Correia","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","article-title":"Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis","volume":"6","author":"Gilmore","year":"2020","journal-title":"JAAD Case Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1298988","DOI":"10.3389\/fmed.2023.1298988","article-title":"Expert opinions and clinical experiences with chlormethine gel as maintenance treatment for patients with mycosis fungoides","volume":"10","author":"Geskin","year":"2023","journal-title":"Front Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s12325-022-02219-w","article-title":"Chlormethine gel for patients with mycosis fungoides cutaneous T cell lymphoma: a review of efficacy and safety in clinical trial and real-world settings","volume":"39","author":"Wehkamp","year":"2022","journal-title":"Adv Ther"},{"article-title":"Incidence and types of contact dermatitis after chlormethine gel treatment in patients with mycosis fungoides-type cutaneous T-cell lymphoma: the MIDAS study","year":"2020","author":"Gilmore","key":"ref34"},{"key":"ref35","first-page":"1","article-title":"Chlormethine gel (Ledaga)","volume":"2","year":"2022","journal-title":"Can J Health Technol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jaad.2021.06.896","article-title":"Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study","volume":"87","author":"Querfeld","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1474030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:25:16Z","timestamp":1734355516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1474030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":36,"alternative-id":["10.3389\/fmed.2024.1474030"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1474030","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1474030"}}